Objective, peer-reviewed reporting on therapeutic peptides, regulatory updates, clinical trial results, and scientific consensus. No hype. No product sales.
Articles tagged metabolic-health.
Discover the latest retatrutide weight loss results from the Phase 3 TRIUMPH-1 trial. Learn how this triple agonist peptide achieves bariatric-level results.
Injectable peptide stacks are surging on social media. Alex Keane explains how to separate GLP-1 evidence from the BPC-157, TB-500, and wellness-peptide evidence gap.
Retatrutide is surging in search and social conversation. Alex Keane explains the triple-agonist science, clinical data, and online peptide safety risks behind today’s trend.
Retatrutide is driving a new wave of peptide searches after Phase 3 weight-loss data. Alex Keane explains the triple-agonist science, safety signals, and why online peptide products deserve caution.
Retatrutide and BPC-157 are driving today’s peptide safety debate. Alex Keane explains why GLP-1 science, recovery peptides, and evidence gaps are colliding in 2026.
No articles match that search.